Recent Updates
Recently added Catalysts
MYO Positive Sentiment

Myomo Reports First Quarter 2025 Financial and Operating Results

Wednesday, May 7, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Myomo, Inc. reported strong financial results for Q1 2025, with revenue reaching $9.8 million. The company added a record 700 patients to its pipeline and has trained over 300 Certified Prosthetists Orthotists in its MyoPro® device. A conference call is scheduled for later today to discuss these results.
Price reaction · baseline $4.8 (2025-05-07T17:09:00.000Z) · hit during market hours · clean, no other MYO news in the window
day 0 close · peak
+0.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Revenue increased to $9.8 million.
  • Record 700 patients added to the pipeline.
  • Over 300 Certified Prosthetists Orthotists trained.

Full Press Release Details

Revenue of $9.8 million
Record 700 patients added to the pipeline
More than 300 Certified Prosthetists Orthotists have completed initial MyoPro® training
Conference call being held today at 4:30pm Eastern time
BURLINGTON, Mass. (May 7, 2025) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2025.
Financial and operating highlights for the first quarter of 2025 include the following (all comparisons are with the first quarter of 2024 unless otherwise indicated): Read more.

Frequently Asked Questions

What was Myomo's revenue for Q1 2025?

Myomo reported a revenue of $9.8 million for Q1 2025.

How many patients were added to Myomo's pipeline?

A record 700 patients were added to Myomo's pipeline in Q1 2025.

How many professionals completed MyoPro training?

More than 300 Certified Prosthetists Orthotists completed MyoPro training.

When is Myomo's conference call?

Myomo's conference call is scheduled for today at 4:30 PM Eastern time.

ShareAdd on Google
Tags: MYO Viatris Investor Conferences Healthcare Myomo financial results Q1 2025 MyoPro
Last updated: May 7, 2025

Biotech snapshot

Cash runway
$13M liquidity · $1M/mo burn
~20 mo
Low dilution risk